World Health Assembly 78

The World Hepatitis Alliance, the Union for International Cancer Control (UICC), Coalition for Global Hepatitis Elimination (CGHE), Medicines Patent Pool and Infectious Disease Alliance, with technical support from the World Health Organization (WHO), are co-hosting a special event at the Seventy-eighth World Health Assembly.

The session will explore the connection between communicable diseases and cancer, and discover how the growing mortality from cancer and non-communicable diseases (NCDs) can be addressed through better integration. 

NCDs and communicable diseases are inextricably linked, but the connection is often overlooked. Many deaths could be averted by preventing the communicable diseases that lead to NCDs like cancer.

As part of the session, the World Hepatitis Alliance will launch a white paper on liver cancer and chronic hepatitis. This sets out a series of policy recommendations that could be transformative in the prevention and early diagnosis of liver cancer.

Speakers

  • Meg Doherty, Director of the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes (HHS), World Health Organization
  • Jessica Hicks, Senior Director, World Hepatitis Alliance
  • Charles Gore, Executive Director, Medicines Patent Pool
  • Dr Kirstie Graham, Director Capacity Building, UICC
  • Rodrigo Scotini, Executive Director, Infectious Disease Alliance
  • John Ward, Director, Coalition for Global Hepatitis Elimination

 

We look forward to seeing you there!

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close